Press release
Investigation announced for Investors in shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS)
An investigation for investors in Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) shares over potential securities laws violations.
Investors who purchased shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Xeris Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Chicago, IL based Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations.
On or around June 20, 2018, Xeris conducted its initial public offering ("IPO"), selling 5,700,000 shares of common stock priced at $15.00 per share.
On March 9, 2021, Xeris Pharmaceuticals, Inc announced its fourth quarter and full year 2020 results. Xeris Pharmaceuticals, Inc. reported that its annual Total Revneue rose from $2.72 million in 2019 to $20.15 million in 2020, and that its Net Loss declined from $125.58 million in 2019 to $91.13 million in 2020. However, Xeris Pharmaceuticals, Inc reported fourth quarter GAAP earnings per share of $0.41, missing consensus estimates by $0.01, and revenue of $7.09 million, missing consensus estimates by $1.82 million.
Shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) declined to $3.98 per share on March 9, 2021.
Those who purchased shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) here
News-ID: 2257314 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for Xeris
Congenital Hyperinsulinism Market to Exhibit Moderate Growth Rate till 2032, Inv …
DelveInsight's "Congenital Hyperinsulinism Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Congenital Hyperinsulinism Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Congenital Hyperinsulinism market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size…
Congenital Hyperinsulinism Market Accelerating CAGR +4% by 2028 with Teva Pharma …
Congenital Hyperinsulinism Market is projected to thrive at a CAGR +4% by the timeline of 2021-28.
Congenital hyperinsulinism is a rare genetic condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent episodes of low blood sugar (hypoglycemia).
Congenital Hyperinsulinism be cured by diffusing CHI affects the entire pancreas. It can be inherited in a…
Investigation announced for Investors in shares of Xeris Pharmaceuticals, Inc. ( …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Xeris Pharmaceuticals, Inc.
Investors who purchased shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Xeris Pharmaceuticals, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Chicago,…
The subcutaneous biologic drugs and affiliated technologies market is projected …
Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals
Roots Analysis is pleased to announce the publication of its recent study, titled “Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030” report to its list of offerings.
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
The report provides…
The subcutaneous biologic drugs and affiliated technologies market is projected …
Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals
Roots Analysis is pleased to announce the publication of its recent study, titled “Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030” report to its list of offerings.
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
The report provides…
Glucagon Market Size, Share, Trends, Regional Analysis & Forecast 2027 | Players …
Stratagem Market Insights has announced the addition of the "Glucagon Market Report 2020-2027 Production, Sales And Consumption Status And Prospects Professional Research", The report classifies the global Glucagon Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.
The Glucagon Market report is a compilation of first-hand information, qualitative and competitive assessment industry analysts, inputs from industry experts and industry…
